APA

Kumar S. K., Ma E., Engebretson A. E., Buadi F. K., Lacy M. Q., Dispenzieri A., Duh M. S., Lafeuille M., Lefebvre P., Cheng W. Y., Dea K., Rembert D., Patt D., Niculescu L., Quick M. & Rajkumar S. V. (20160915). Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. : Leukemia.

Chicago

Kumar S K, Ma E, Engebretson A E, Buadi F K, Lacy M Q, Dispenzieri A, Duh M S, Lafeuille M-H, Lefebvre P, Cheng W Y, Dea K, Rembert D, Patt D, Niculescu L, Quick M and Rajkumar S V. 20160915. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. : Leukemia.

Harvard

Kumar S. K., Ma E., Engebretson A. E., Buadi F. K., Lacy M. Q., Dispenzieri A., Duh M. S., Lafeuille M., Lefebvre P., Cheng W. Y., Dea K., Rembert D., Patt D., Niculescu L., Quick M. and Rajkumar S. V. (20160915). Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. : Leukemia.

MLA

Kumar S K, Ma E, Engebretson A E, Buadi F K, Lacy M Q, Dispenzieri A, Duh M S, Lafeuille M-H, Lefebvre P, Cheng W Y, Dea K, Rembert D, Patt D, Niculescu L, Quick M and Rajkumar S V. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. : Leukemia. 20160915.